Summary Two 9-dihydrotaxane analogues were synthesised and tested for in vitro potency and in vivo efficacy against murine and human tumour xenografts in mice. The in vitro potency of 9-dihydrotaxol (9-DH-t) and 10-deacetyl-9-dihydrotaxol (10-DeAc-9-DH-t) was generally less than that of paclitaxel against human and murine tumour cells. However, both analogues were at least 20-fold more soluble than paclitaxel in water. The analogues yielded cure rates > 60% against human MX-1 solid tumour xenografts in mice, compared with a cure rate of 10% for mice treated with paclitaxel. Both of the analogues were more effective than paclitaxel for treatment of murine M 109 solid tumour in mice. 1 O-DeAc-9-DH-t was as effective as paclitaxel against murine B16 ascites tumour, while 9-DH-t was less effective. Both 10-DeAc-9-DH-t and 9-DH-t were demonstrably less toxic than paclitaxel. At equal dosages 9-DH-t produced serum concentrations greater than paclitaxel, while 10-DeAc-9-DH-t yielded serum concentrations less than paclitaxel. However, the decrease in toxicity of 9-DH-t and 10-DeAc-9-DH-t allowed a 4-fold increase in daily dosage. These two 9-dihydrotaxane analogues yielded favourable preclinical data and demonstrated good potential for further development.
As a new anti-cancer drug, paclitaxel has promising efficacy but considerable clinical limitations owing to issues of supply, solubility and toxicity. Paclitaxel is obtained from the bark of the Pacific yew, Taxus brevifolia, and has demonstrated potent in vitro cytotoxicity against murine and human cells (Wani et al., 1971; NCI, 1990) . The mechanism of action involves stabilisation of microtubles with inhibition of depolymerisation to free tubulin (Fuchs and Johnson, 1978; Schiff et al., 1979; Schiff, 1980) . This unique mechanism stimulated development of paclitaxel despite initial limitations in the supply of Taxus brevifolia. A commercially viable synthetic route for paclitaxel is lacking, although a semisynthetic route has helped ease the supply shortage. Toxicity is the major factor limiting paclitaxel dosage and potentially successful therapy. Paclitaxel also suffers from limited solubility, necessitating the use of a cremophor vehicle, which itself may induce toxicity. The development of docetaxel demonstrated that analogues of paclitaxel can have clinical potential (Bissery et al., 1991) .
A novel taxane congener was recently isolated from an extract of the Canadian bush Taxus canadensis (Gunawardana, 1992) . The novel structure of this compound and the relatively good supply of Taxus canadensis allowed for the preparation of 9-dihydrotaxol (Klein, 1993) and ring Brearranged taxane analogues . The fallen needles and twigs of Taxus canadensis can be used in preparation of starting material, eliminating the need to harvest the entire bush. The 9-dihydrotaxane analogues retain in vitro cytotoxicity comparable with paclitaxel and the mechanism of action appears to be identical to that of paclitaxel .
Two taxane analogues prepared from Taxus canadensis starting material were tested for in vivo efficacy against murine and human tumours. Efficacy was determined against both ascites and solid tumours, including human tumour xenografts. In vitro cytotoxicity, solubility and pharmacokinetic data were also determined for the analogues. The two paclitaxel analogues presented in this report demonstrate promising toxicity and efficacy data relative to paclitaxel. The results support further development of these paclitaxel analogues.
Methods

Synthesis of taxane analogues
The synthesis of the taxane analogues (Figure 1 ) has been described in detail previously Li et al., 1994) . Paclitaxel was obtained from NaPro Biotherapeutics, Boulder, CO, USA.
In vitro evaluation of anti-tumour compounds The in vitro potency of experimental and control taxanes was determined using a colorimetric assay to assess cell cytotoxicity as described previously (Chu et al., 1992 Figure 1 Structures of the paclitaxel analogues 9-DH-t and 10-DeAc-9-DH-t. A-85576, 9-DH-t; Rl =Ac; A-86415, 10-DeAc-9- 
Dosing
The taxanes were dissolved in 100% ethanol, which was then diluted with cremophor to yield a 50:50 mixture. The solutions were diluted with sterile injectable water (Abbott Labs, North Chicago, IL, USA) to yield appropriate concentrations, and were administered in a volume of 0.5 ml i.p. The final volumes of ethanol and cremophor (Sigma, St Louis, MO, USA) combined were no more than 12% (6% each). The initial dose was administered 1 day after tumour inoculation. Against B16FIO and MX-1 tumours the taxane analogues were administered once daily for 5 consecutive days (days 1 -5 after inoculation). Against M109 subcutaneous tumours the taxane analogues were administered once daily, every fourth day for a total of three injections (days 1, 5, 9 after inoculation). The schedules for drug administration were adapted from general National Cancer Institute guidelines for preclinical testing of antitumour agents (NCI, 1985; Gerari et al, 1972 
Results
In vitro cell cytotoxicity
The paclitaxel analogues A-85576, 9-dihydrotaxol (9-DH-t), and A-86415, 10-deacetyl-9-dihydrotaxol (10-DeAc-9-DH-t), produced IC50 values that ranged from equally to 8-fold less potent than paclitaxel (Table I) . 10-DeAc-9-DH-t was as ane ml-to produce 50% cytotoxicity in the indicated tumour cell line. Water solubility potent as paclitaxel against HT29 and P388 tumour cells, but was 3-to 8-fold less potent vs A549 and B16F10 cells respectively. 9-DH-t was 3-to 5-fold less potent than paclitaxel against the four tumour cell lines. The water solubility of 9-DH-t was approximately 75-fold greater than paclitaxel. The water solubility of 10-DeAc-9-DH-t was approximately 20-fold that of paclitaxel.
In vivo MTD doses in mice When administered i.p. once daily for 5 consecutive days, the maximum tolerated dose (MTD) of paclitaxel was 25 mg kg-' day-', while the MTDs of 9-DH-t and 10-DeAc-9-DH-t were greater than 100 mg kg-' day-'. The MTDs were determined in BDF mice bearing B16FlO ascites tumours (Table II) . Efficacy of taxane analogues vs i.p. B16F10 murine melanoma At non-toxic doses the paclitaxel analogues 9-DH-t and 10-DeAc-9-DH-t optimally produced 39% and 83% increase in life span (ILS) and cure rates of 0% and 10% respectively (Table III) . Paclitaxel treatment produced a 96% ILS and a 0% cure rate. Untreated mice survived approximately 20 days. The optimal dosage for paclitaxel was 25 mg kg-' day-' when administered i.p. once daily for 5 consecutive days. On the same schedule the optimal doses of the paclitaxel analogues 9-DH-t and 10-DeAc-9-DH-t were 50
and 100 mg kg-' day-'. There was a dose-response effect to paclitaxel and the analogues.
Efficacy of taxane analogues vs subcutaneous M109 murine solid tumour The paclitaxel analogues 9-DH-t and 10-DeAc-9-DH-t yielded 10.5 and 5.1 day delays in solid tumour growth to 1 g (Table IV ). Paclitaxel at a non-toxic dose produced only a 0.6 day delay in tumour growth to 1 g. Untreated mice yielded tumours with a mass of 1 g in 12 days. There was a 0% cure rate for all compounds. The tumour weight inhibition. (TWI) when untreated mice had a mean tumour mass of 1 g was 79 -90% for the taxane analogues, compared with 47% for mice treated with paclitaxel. When administered i.p on a schedule of every fourth day for three total injections (days 1, 5, 9 after inoculation), the optimal doses of 9-DH-t and 10-DeAc-9-DH-t were 100 mg kg-' injection. There was a general dose reponse to all three compounds. Pharmacokinetic properties of taxane analogues following i.p. dosing in mice 9-DH-t yielded Cmax values of 40 jg ml-' plasma at 0.5 h after dosing (Table VI) . The AUC value of over 75 pgh-' ml-' for 9-DH-t was the largest value observed for the three compounds. 10-DeAc-9-DH-t produced a Cmax of 11 jIg ml -' at 1.5 h after administration. The AUC value for 10-DeAc-9-DH-t was 30 jig h-' ml-'. Paclitaxel yielded a Cmax of 14 jig ml-' at 1.5 h after administration and an AUC value of 43 jg h-' ml-'. The t1/2 values for 9-DH-t, 10-DeAc-9-DH-t and paclitaxel were 1.9, 2.8, 2.9 h.
Discussion
The two taxane analogues showed favourable solubility, toxicity and efficacy profiles relative to paclitaxel. Both 10-DeAc-9-DH-t and 9-DH-t demonstrated less toxicity than paclitaxel, and considerable efficacy vs murine and human solid tumours in vivo. A decrease in lethal toxicity allowed higher daily doses to be administered for the analogues. The in vitro potency of the taxane analogues was within one log of that of paclitaxel, but there was no clear correlation between in vitro potency and in vivo efficacy.
The mouse models of tumour growth are valid indicators of potential clinical utility of paclitaxel analogues. Both ascites and solid tumour mouse models are commonly used as screens for preclinical efficacy (Gerari et al., 1972 Both of the analogues demonstrated efficacy that compared favourably with paclitaxel vs murine M109 and human MX-1 solid tumour xenograft. The efficacy of paclitaxel vs M109 in these trials was less than that reported previously (Rose, 1981 (Rose, , 1991 bioavailability for both analogues. The serum levels and AUC values of 9-DH-t were greater than paclitaxel, while the serum levels of 10-DeAc-9-DH-t was less than paclitaxel at equal dosages. The t,/2 values for 9-DH-t and paclitaxel were similar (2.8 and 2.9 h), suggesting a potential dosing advantage for the analogue based on the decrease in toxicity. Pharmacokinetic studies in mice must be interpreted with caution owing to the higher variability between animals. The decrease in apparent toxicity of the analgoues relative to paclitaxel was encouraging. The analogues were tolerated at daily i.p. doses of 100 mg kg-' day-', which was 4-fold greater than paclitaxel. This decrease in toxicity allowed the analogues to be administered at higher doses, resulting in greater efficacy. Some reports suggest that daily doses of paclitaxel may be superior to larger, less frequent doses (NCI, 1985) . Both 9-DH-t and 10-DeAc-9-DH-t were better tolerated than paclitaxel. In general, nude mice did not tolerate daily doses of the taxane analogues as well as other mice and paclitaxel showed variability in maximum tolerated dose between trials. In the M109 and MX-1 solid tumour trials paclitaxel at 25 mg kg-' was not tolerated (30% and 40% mortality), while daily doses of 25 mg kg-' were tolerated in the B 16 ascites tumour trials. The optimal balance of efficacy and toxicity has not been yet been determined with taxane analogues.
The efficacy of the taxane analogues relative to paclitaxel suggests potential clinical utility. Paclitaxel has demonstrated clinical efficacy vs human breast and ovarian tumours (McGuire et al., 1989; Thigpen et al., 1990) . Reponse rates of 48% were recorded in breast tumour patients who had failed one previous course of chemotherapy (Holmes et al., 1991) . Paclitaxel has been used against other tumours, including leukaemia and malignant melanoma (Einzig, 1988; Rowinsky et al., 1989) . A 30% response rate against ovarian tumours that had failed cisplatinum therapy was obtained with paclitaxel (McGuire et al., 1989) . The clinical use and efficacy of docetaxel has generated additional support for this base structure (Chabner et al., 1991; Ringel and Horwitz, 1993) . The preclinical efficacy and toxicity profiles of the taxane analogues in relation to paclitaxel may be extended to project potential clinical use.
In summary, two taxane analogues were tested for efficacy in mouse models of solid and ascites tumours. These analogues were generally superior or similar to paclitaxel in efficacy. The analogues 9-DH-t and 10-DeAc-9-DH-t yielded less toxicity and greater water solubility than paclitaxel. The preclinical efficacy of these two compounds supports further development.
Abbreviations 9-DH-t, 9-dihydrotaxol; 10-DeAc-9-DH-t, 1 0-deacetyl-9-dihydrotaxol; IC50, 50% inhibitory concentration; %ILS, per cent increase in lifespan; TWI, tumour weight inhibition; Cmax, maximum serum concentration; Tmax, time to maximum concentration; AUC, area under the curve; LD50, 50% lethal dose; MTD, maximum tolerated dose.
